TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma

NCT02396511 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

2

Enrollment

INDUSTRY

Sponsor class

Conditions

Choriocarcinoma

Interventions

BIOLOGICAL: TRC105
BIOLOGICAL: Bevacizumab

Sponsor

Tracon Pharmaceuticals Inc.